CXCL10 Is a Possible Biomarker for the Development of Psoriatic Arthritis Among Patients With Psoriasis
CXCL10 Is a Possible Biomarker for the Development of Psoriatic Arthritis Among Patients With Psoriasis
复制标题
DOI：
10.1002/art.39800
复制
发表时间：
2016-12-01
影响因子：
13.3
通讯作者：
Gladman, Dafna D.
中科院分区：
文献类型：
--
作者：
Abji, Fatima;Pollock, Remy A.;Gladman, Dafna D.
客观的。可以预测银屑病患者银屑病关节炎（PsA）发展的生物标志物在临床实践中将很有用。本研究的目的是评估 CXCL10 是否可以作为 PsA 发病前的预测生物标志物。方法。对没有关节炎的银屑病患者进行前瞻性随访，并每年由风湿病学家评估银屑病关节炎的发生情况。发生 PsA 的患者被指定为转化者，而未发生 PsA 的患者被称为非转化者。通过 Luminex 测定法测量 46 名转化者和 45 名未转化者的 CXCL10 基线血清浓度。结果。转化者中的 CXCL10 水平（中位数 493 pg/ml [四分位距 (IQR) 356-984]）显着高于非转化者（中位数 371 pg/ml [IQR 263-578]；P=0.005）。相比之下，基线时转化者和非转化者之间的 C 反应蛋白 (CRP) 水平没有显着差异。调整年龄、性别、银屑病病程和随访时间后，CXCL10 与转化状态相关（比值比 1.3，95% 置信区间 1.1-1.5，P=0.004）。在转化者的子集中，基线时的 CXCL10 水平（中位数 927.4 pg/ml [IQR 547.6-1,243]）显着高于 PsA 诊断后（491.5 pg/ml [IQR 323.2-607]；P < 0.0001），而基线时 CRP 水平较低（26.6 μg/ml [IQR]） 16.37-62.75]）高于 PsA 诊断后（36.1 μg/ml [IQR 14.74-101.7]；P=0.003）。与PsA患者的血液相比，CXCL10基因表达在滑液（SF）中增加17.3倍（P=0.01），在PsA患者的SF中比痛风患者的SF增加44.3倍（P=0.001）。结论。 CXCL10 可能参与 PsA 发病机制，是银屑病患者 PsA 的候选预测生物标志物。
Objective. Biomarkers that can predict the development of psoriatic arthritis (PsA) in patients with psoriasis would be useful in clinical practice. The aim of this study was to assess whether CXCL10 could be a predictive biomarker of PsA prior to its onset.Methods. Psoriasis patients without arthritis were followed up prospectively and assessed annually for development of PsA by a rheumatologist. Patients in whom PsA developed were designated as converters, while those in whom PsA did not develop were termed nonconverters. Baseline serum concentrations of CXCL10 were measured by Luminex assay in 46 converters and 45 nonconverters.Results. The level of CXCL10 was significantly higher in converters (median 493 pg/ml [interquartile range (IQR) 356-984]) than in nonconverters (median 371 pg/ml [IQR 263-578]; P=0.005). In contrast, C-reactive protein (CRP) levels were not significantly different between converters and nonconverters at baseline. CXCL10 was associated with conversion status after adjustment for age, sex, duration of psoriasis, and duration of follow-up (odds ratio 1.3, 95% confidence interval 1.1-1.5, P=0.004). In a subset of converters, the CXCL10 level was significantly higher at baseline (median 927.4 pg/ml [IQR 547.6-1,243]) than after PsA diagnosis (491.5 pg/ml [IQR 323.2-607]; P < 0.0001), while CRP levels were lower at baseline (26.6 mu g/ml [IQR 16.37-62.75]) than after PsA diagnosis (36.1 mu g/ml [IQR 14.74-101.7]; P=0.003). CXCL10 gene expression was increased 17.3-fold in synovial fluid (SF) compared with blood from PsA patients (P=0.01) and 44.3-fold in the SF of PsA patients compared with the SF of patients with gout (P=0.001).Conclusion. CXCL10 may be involved in PsA pathogenesis and is a candidate predictive biomarker for PsA in patients with psoriasis.